ITGAX and hepatocellular carcinoma: found that combining i.v. MIP‐1α therapy with preestablished methods of treatment for hepatocellular carcinoma, such as irradiation or sorafenib, significantly enhanced antitumor immunity dependent on increased CD8+, CD107A+, and CD11C+ cells.